AKRO
Price
$30.22
Change
-$0.39 (-1.27%)
Updated
Dec 18, 10:39 AM (EDT)
85 days until earnings call
BEAM
Price
$28.50
Change
-$0.08 (-0.28%)
Updated
Dec 18, 10:59 AM (EDT)
76 days until earnings call
Ad is loading...

AKRO vs BEAM

Header iconAKRO vs BEAM Comparison
Open Charts AKRO vs BEAMBanner chart's image
Akero Therapeutics
Price$30.22
Change-$0.39 (-1.27%)
Volume$1.27K
CapitalizationN/A
Beam Therapeutics
Price$28.50
Change-$0.08 (-0.28%)
Volume$9.15K
CapitalizationN/A
AKRO vs BEAM Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. BEAM commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and BEAM is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (AKRO: $30.61 vs. BEAM: $28.58)
Brand notoriety: AKRO and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 129% vs. BEAM: 130%
Market capitalization -- AKRO: $2.14B vs. BEAM: $2.37B
AKRO [@Biotechnology] is valued at $2.14B. BEAM’s [@Biotechnology] market capitalization is $2.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • AKRO’s TA Score: 4 bullish, 6 bearish.
  • BEAM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than AKRO.

Price Growth

AKRO (@Biotechnology) experienced а -0.10% price change this week, while BEAM (@Biotechnology) price change was -5.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.84%. For the same industry, the average monthly price growth was +1.08%, and the average quarterly price growth was +4.66%.

Reported Earning Dates

AKRO is expected to report earnings on Mar 13, 2025.

BEAM is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-4.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.37B) has a higher market cap than AKRO($2.14B). AKRO YTD gains are higher at: 31.092 vs. BEAM (4.996).
AKROBEAMAKRO / BEAM
Capitalization2.14B2.37B90%
EBITDAN/AN/A-
Gain YTD31.0924.996622%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
AKROBEAM
RSI
ODDS (%)
N/A
Bearish Trend 6 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+4.72%
ETNB - AKRO
63%
Loosely correlated
+1.01%
DNLI - AKRO
45%
Loosely correlated
-0.30%
PLRX - AKRO
45%
Loosely correlated
+4.74%
BEAM - AKRO
44%
Loosely correlated
-1.21%
IDYA - AKRO
42%
Loosely correlated
+1.07%
More

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-1.21%
CRSP - BEAM
72%
Closely correlated
+0.88%
NTLA - BEAM
65%
Loosely correlated
-1.87%
DNLI - BEAM
65%
Loosely correlated
-0.30%
PRME - BEAM
62%
Loosely correlated
-3.00%
RXRX - BEAM
61%
Loosely correlated
-4.30%
More